[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 187
1. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. McMillan A: Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol; 2005 Oct;131(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All adult patients with Burkitt lymphoma or lymphoblastic lymphoma should receive central nervous system (CNS)-directed therapy with both intrathecal and high-dose systemic chemotherapy.
  • There is no evidence to support the routine use of prophylactic CNS-directed therapy in any specific subgroup of adult patients with 'low grade' lymphomas.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / prevention & control. Female. Humans. Injections, Spinal. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Prognosis. Recurrence. Risk Assessment

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173958.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 47
  •  go-up   go-down


3. Yang W, Agrawal N, Patel J, Edinger A, Osei E, Thut D, Powers J, Meyerson H: Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom; 2005 Jan;63(1):28-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased CD19 expression was noted in 79% of follicular lymphomas (27 of 34), 36% of small lymphocytic lymphomas/chronic lymphocytic leukemias (82 of 228), 31% of mantle cell lymphomas (4 of 13), 24% of diffuse large B-cell lymphomas (8 of 33), and 13% of marginal zone B-cell lymphomas/lymphoplasmacytoid lymphomas (4 of 30) and was not observed in any Burkitt lymphoma (0 of 5) or hairy cell leukemia (0 of 6).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. B-Lymphocytes / cytology. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Bone Marrow Cells / immunology. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Humans. Middle Aged

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15624204.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19
  •  go-up   go-down


Advertisement
4. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, Jeandel R, Khoury E, Martelli JM, Samson T, Tapia S, Flandrin G, Troussard X: Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma; 2006 Sep;47(9):1885-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
  • Out of 344 patients with newly diagnosed non-Hodgkin's lymphoma (NHL), this study identified 16 patients presenting Burkitt-like cells (BLCs) after cytological and/or histological review.
  • These data could suggest a sub-group of NHL patients (15 B-NHL, 1 T-NHL) have been identified with a poor prognosis characterized by the association of Burkitt-like cells and c-MYC amplification without t(8;14)(q24;q32) or its variants.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Amplification. Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Cytogenetic Analysis. Female. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Male. Middle Aged. Prognosis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065002.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


5. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia; 2005 Jun;19(6):945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
  • The feasibility and efficacy of up-front high-dose sequential chemotherapy followed by autologous stem cell transplantation (ASCT) in previously untreated adults (median age 33 years; range 15-64) with Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or lymphoblastic lymphoma (LyLy), both without central nervous system or extensive bone marrow involvement was investigated in a multicenter phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800666.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


6. Wu JY, Huang XJ: [Investigation of plasmacytoid dendritic cell reconstitution and its relationship with cGVHD and relapse after haploidentical hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the characteristics and significance of reconstitution of peripheral blood plasmacytoid dendritic cell (PDC) precursors after allogeneic human leukocyte antigen mismatched/haploidentical hematopoietic stem cell transplantation, and its relationship with chronic graft versus host disease (cGVHD) and relapse, 19 patients with leukemia were enrolled for this study.
  • The results showed that compared with healthy subjects, patients with leukemia had a significantly decreased proportion and absolute number of myeloid dendritic cell (MDC), MDC1, DC and the ratio of MDC/PDC (P<0.05).
  • It is concluded that compared with healthy subjects, de novo leukemia patients have a significantly decreased proportion and absolute number of DC and the ratio of MDC/PDC before haploidentical hematopoietic stem cell transplantation; while ratio of MDC/PDC can be normalized with relative rapidity, the proportions of all DC subsets reached to normal levels on the whole at 9 months after transplantation, and also recovery level of DCs is correlated with occurrence of cGVHD and relapse.


7. Olsen M, Madsen HO, Hjalgrim H, Gregers J, Rostgaard K, Schmiegelow K: Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood. J Pediatr Hematol Oncol; 2006 Nov;28(11):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cell precursor acute lymphoblastic leukemia (ALL), where it occurs in 25% of all cases.
  • In contrast, the translocation is seen in only 3% of adult ALL cases.
  • These data indicates that prenatal TEL-AML1 subclones does not persist throughout adult life at cell levels of 10 to 10.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Preleukemia / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Blood Donors. Child. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114960.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


8. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R: Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica; 2007 Mar;92(3):342-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
  • BACKGROUND AND OBJECTIVES: The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial.
  • The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated.
  • DESIGN AND METHODS: We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol.
  • RESULTS: MyAg expression was documented in 35% of the 377 adult ALL cases analyzed.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Cell Count. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / mortality. Burkitt Lymphoma / radiotherapy. Cell Lineage. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339183.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; EC 3.4.11.2 / Antigens, CD13; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K: Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol; 2010 Dec;92(5):732-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
  • The feasibility and efficacy of cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL (intermediate DLBCL/BL) have never been reported.
  • In conclusion, our modified CODOX-M/IVAC regimen is well tolerated and highly effective in Japanese adult patients with BL and intermediate DLBCL/BL, warranting a larger study for confirmation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Cancer Sci. 2008 Sep;99(9):1760-8 [18549405.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2471-8 [1421370.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2009 May 14;113(20):4834-40 [19264918.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):246-52 [18271922.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Int J Hematol. 2008 May;87(4):393-7 [18409079.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):59-68 [16831590.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):935-40 [8622042.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):443-7 [18855101.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):847-58 [3711961.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]
  • (PMID = 21120644.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


11. Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Kees UR: In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br J Haematol; 2007 Apr;137(2):109-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
  • The in vitro efficacies of three new drugs--clofarabine (CLOF), nelarabine (NEL) and flavopiridol (FP) - were assessed in a panel of acute lymphoblastic leukaemia (ALL) cell lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adenine Nucleotides / pharmacology. Arabinonucleosides / pharmacology. Burkitt Lymphoma / pathology. Child. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Flavonoids / pharmacology. Humans. Inhibitory Concentration 50. Leukemia-Lymphoma, Adult T-Cell / pathology. Piperidines / pharmacology. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2011 Aug;154(4):541
  • (PMID = 17391490.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Flavonoids; 0 / Piperidines; 45AD6X575G / alvocidib; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  •  go-up   go-down


12. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma; 2007 Aug;48(8):1522-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / radiography. Burkitt Lymphoma / radionuclide imaging. Humans. International Cooperation. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiography. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Practice Guidelines as Topic. Predictive Value of Tests. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701583.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Teruya-Feldstein J: Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep; 2005 Sep;7(5):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, PBL associated with multicentric Castleman disease, DLBCL with secretory differentiation, pyothorax-associated lymphoma, and atypical Burkitt lymphoma with plasmacytoid differentiation have morphologic appearances of plasma cell differentiation but maintain a mature B-cell (CD20 positive) phenotype.
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. B-Lymphocytes / cytology. Cell Differentiation. Cell Proliferation. Empyema, Pleural / metabolism. Giant Lymph Node Hyperplasia / metabolism. Giant Lymph Node Hyperplasia / therapy. Humans. Lymphoma / metabolism. Male. Middle Aged. Mouth Mucosa / pathology. Multiple Myeloma / metabolism. Neoplasms / metabolism. Phenotype. Plasmacytoma / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2001 Aug 17;15(12):1483-91 [11504980.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1537-8; author reply 1538 [15489660.001]
  • [Cites] Blood. 2000 May 15;95(10):3204-7 [10807789.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Clin Pathol. 1996 Mar;49(3):205-7 [8675729.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):230-42 [15738953.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Histopathology. 1997 Mar;30(3):256-9 [9088955.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1660-8 [15479729.001]
  • [Cites] J Pathol. 2005 Jan;205(1):92-101 [15586381.001]
  • [Cites] J Am Coll Surg. 2004 Oct;199(4):654-5 [15454154.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):254-63 [14983940.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):35-9 [15660653.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1538-40; author reply 1540 [15489661.001]
  • [Cites] Mod Pathol. 1997 Sep;10(9):927-32 [9310957.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Histopathology. 2005 Mar;46(3):241-55 [15720410.001]
  • [Cites] Pathol Res Pract. 1997;193(9):613-6 [9521019.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] Leukemia. 2004 Jan;18(1):146-55 [14603341.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1251-2 [15316328.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):485-9 [9378814.001]
  • [Cites] Histopathology. 2005 Mar;46(3):348-50 [15720425.001]
  • [Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):909-15 [11298585.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Histopathology. 2005 Jan;46(1):113-5 [15656898.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2812-20 [15576473.001]
  • (PMID = 16091196.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Number-of-references] 50
  •  go-up   go-down


14. Mantina H, Wiggill TM, Carmona S, Perner Y, Stevens WS: Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr; 2010 Apr;53(5):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV prevalence ranged from an absence in follicular or mantle cell lymphoma to a low prevalence in diseases like small lymphocytic lymphoma/chronic lymphocytic leukemia (4%) and pre-B/common ALL (5%) to a high prevalence in diffuse large B-cell lymphoma (80%), Burkitt lymphoma/leukemia (86%), and primary effusion lymphoma (100%).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Viral / blood. Child. Child, Preschool. DNA, Viral / chemistry. DNA, Viral / genetics. Enzyme-Linked Immunosorbent Assay. Female. Humans. Infant. Male. Middle Aged. Polymerase Chain Reaction. Prevalence. Retrospective Studies. South Africa / epidemiology. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Acquir Immune Defic Syndr. 2010 Jun;54(2):221
  • (PMID = 20160652.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral
  •  go-up   go-down


15. Akamatsu N, Yamada Y, Hasegawa H, Makabe K, Asano R, Kumagai I, Murata K, Imaizumi Y, Tsukasaki K, Tsuruda K, Sugahara K, Atogami S, Yanagihara K, Kamihira S: High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett; 2007 Oct 28;256(2):196-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We surveyed IL-21 receptor (IL-21R) in leukemia and lymphoma and found that follicular lymphoma cells showed exceptionally high IL-21R expression.
  • Notably, IL-21 showed divergent effects depending on the cell origin: growth stimulation in Burkitt lymphoma cell lines and adult T cell leukemia/lymphoma cell lines but induction of apoptosis in B lymphoma cell lines with t(14;18)(q32;q21), a marker karyotype of follicular lymphoma.
  • [MeSH-major] Antineoplastic Agents / metabolism. Apoptosis. Interleukins / metabolism. Leukemia / metabolism. Lymphoma, Follicular / metabolism. Receptors, Interleukin-21 / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624663.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Interleukin-21; 0 / Recombinant Proteins; 0 / bcl-2-Associated X Protein; 0 / interleukin-21; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


16. Lin RF, Li JY, Lu H, Wu YJ, Qiu HR, Xiao B, Zhang JF, Yang H: [Bone marrow necrosis as an initial manifestation of Philadelphia chromosome and myeloid antigens positive B acute lymphoblastic leukemia--a case report]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):832-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone marrow necrosis as an initial manifestation of Philadelphia chromosome and myeloid antigens positive B acute lymphoblastic leukemia--a case report].
  • Many diseases cause bone marrow necrosis (BMN), especially lymphocytic leukemia.
  • To explore the complexity of the pathogenesis and pathology of BMN and understand the multiplicity of clinical features, a case of Philadelphia chromosome positive (Ph+) B acute lymphoblastic leukemia (ALL) expressing myeloid antigens was reported.


17. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y: Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control; 2008 Oct;19(8):841-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The best survival was observed for Hodgkin lymphoma among young patients, and the worst survival was observed among cases with plasma cell neoplasms, particularly plasma cell leukemia, in all racial groups.
  • Males typically had lower survival rates than females, but the opposite was observed for Burkitt lymphoma/leukemia among non-whites and multiple myeloma among non-Hispanic whites.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365759.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007864; United States / FIC NIH HHS / TW / 1D43TW007864-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM: Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol; 2008 Jan;32(1):113-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between Burkitt (BL) or atypical Burkitt/Burkitt-like lymphomas harboring a MYC translocation (MYC+) and diffuse large B-cell lymphomas (DLBCLs) with high proliferation fractions but without a MYC translocation (MYC-) can be difficult using standard morphologic and immunohistochemical criteria.
  • Recently, unique gene expression profiles differentiating BL and DLBCL were reported and include higher transcript levels of T-cell leukemia-1 (TCL1) and CD38 and lower transcript levels of CD44 in MYC+ BL relative to MYC- DLBCL.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Male. Middle Aged. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162778.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


19. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.
  • Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another hematologic disorder (acute leukemia) highlights increased sHLA-G secretion.
  • This increased secretion seems more marked in acute leukemia subtypes affecting monocytic and lymphoid lineages such as FABM4 and FABM5, as well as both B and T acute lymphoblastic leukemia (ALL).
  • All these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during acute leukemia.
  • [MeSH-major] Antigens, Neoplasm / blood. HLA Antigens / blood. Histocompatibility Antigens Class I / blood. Leukemia / blood
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


20. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Wang Z, Abubucker S, Martin J, Wilson RK, Hawdon J, Mitreva M: Characterizing Ancylostoma caninum transcriptome and exploring nematode parasitic adaptation. BMC Genomics; 2010;11:307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The generated transcripts from four developmental stages, infective L3, serum stimulated L3, adult male and adult female, covered 93% of the A. caninum transcriptome.
  • Examining the developmental expression profiles of A. caninum revealed major transitions in gene expression from larval stages to adult.
  • Adult males expressed the highest number of selectively expressed genes, but adult female expressed the highest number of selective parasitism-related genes.
  • Parasitism related genes were expressed more selectively in adult male and female worms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2009;533:153-87 [19277558.001]
  • [Cites] BMC Genomics. 2009;10:22 [19144180.001]
  • [Cites] Nat Genet. 1999 Jul;22(3):231-8 [10391209.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1259-67 [15543149.001]
  • [Cites] BMC Bioinformatics. 2004 Nov 30;5:187 [15571632.001]
  • [Cites] BMC Genomics. 2005;6:58 [15854223.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):961-7 [16428741.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1521-32 [16679166.001]
  • [Cites] BMC Bioinformatics. 2007;8:41 [17284313.001]
  • [Cites] Science. 2007 Sep 21;317(5845):1756-60 [17885136.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):282-8 [18171264.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Parasitol Today. 1999 May;15(5):188-93 [10322352.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):452-6 [10581034.001]
  • [Cites] Int J Parasitol. 2000 Apr 10;30(4):347-55 [10731559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3029-33 [11248026.001]
  • [Cites] Bioinformatics. 2001 Sep;17(9):847-8 [11590104.001]
  • [Cites] Mol Biochem Parasitol. 2002 Mar;120(1):1-21 [11849701.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):349-62 [11915948.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Mol Biol. 2004 May 14;338(5):1027-36 [15111065.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] J Parasitol. 1968 Jun;54(3):426-9 [5761146.001]
  • [Cites] Theor Popul Biol. 1975 Apr;7(2):256-76 [1145509.001]
  • [Cites] Annu Rev Physiol. 1981;43:323-41 [7011187.001]
  • [Cites] Mol Biol Evol. 1986 Sep;3(5):418-26 [3444411.001]
  • [Cites] J Parasitol. 1991 Aug;77(4):587-91 [1713962.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Pediatr Res. 1996 Oct;40(4):515-21 [8888276.001]
  • [Cites] Nature. 1997 May 29;387(6632):489-93 [9168109.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):129-37 [9224638.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):71-5 [9510248.001]
  • [Cites] Genome Res. 1998 Jun;8(6):590-8 [9647634.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2012-8 [9851916.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2041-6 [9851921.001]
  • [Cites] Bioinformatics. 1998;14(9):755-63 [9918945.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Mol Biochem Parasitol. 2008 Feb;157(2):187-92 [18082904.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(10):e326 [18958170.001]
  • [Cites] Nat Rev Drug Discov. 2008 Nov;7(11):900-7 [18927591.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D571-8 [18940860.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):289-97 [19042974.001]
  • [Cites] BMC Evol Biol. 2009;9:23 [19175938.001]
  • [Cites] BMC Genomics. 2009;10:114 [19296854.001]
  • (PMID = 20470405.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vaccines
  • [Other-IDs] NLM/ PMC2882930
  •  go-up   go-down


22. Picard C, Hayette S, Bilhou-Nabera C, Cayuela JM, Delabesse E, Frenoy N, Preudhomme C, Dupont M, Bastard C, Bories D, Vaerman JL, Davi F, Dastugue N, Raynaud S, Lafage M, Deschaseaux F, Fest T, Gaub MP, Lhéritier V, Thomas X, Charrin C, Boucheix C, Dombret H, Macintyre E, Fière D, Gabert J: Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. Leukemia; 2006 Dec;20(12):2178-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience.
  • [MeSH-major] Burkitt Lymphoma / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. RNA, Messenger / analysis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039237.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


23. Meleshko AN, Belevtsev MV, Savitskaja TV, Potapnev MP: The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression. Leuk Res; 2006 Jul;30(7):795-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.
  • TCR genes rearrangements were reported to occur at high frequency in B-lineage acute lymphoblastic leukemia (ALL).
  • Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Male. Polymerase Chain Reaction / methods. Recurrence. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386788.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


24. Wilop S, Galm O, Dada R, Osieka R, Jost E: Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leuk Lymphoma; 2008 Nov;49(11):2116-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk factors to develop a decline in platelets after infusion of rituximab were pre-existent thrombocytopenia, advanced lymphoma stage, bone marrow infiltration, splenomegaly, leukemic presentation, and Burkitt lymphoma histology.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Bone Marrow Diseases. Burkitt Lymphoma. Drug Therapy, Combination. Female. Humans. Leukemia. Male. Middle Aged. Platelet Count. Retrospective Studies. Risk Factors. Rituximab. Splenomegaly. Thrombocytopenia. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Nov;49(11):2035-6 [19021044.001]
  • (PMID = 19021054.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


25. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


26. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma; 2006 Sep;47(9):1872-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
  • The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.
  • Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antiretroviral Therapy, Highly Active. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Prednisolone / administration & dosage. Prednisone / therapeutic use. Prognosis. Prospective Studies. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065000.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


27. Huber A, Prosl H, Joachim A, Simpson HV, Pedley KC: Effects of excretory/secretory products of Haemonchus contortus on cell vacuolation. Parasitol Res; 2005 Jul;96(5):290-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used the latter approach to examine, at the cellular level, the effects of ES prepared from L3 and adult nematodes.
  • Both NR uptake and cellular vacuolation were increased following exposure to larval or adult ES products.
  • ES preparations from adult worms induced more extensive vacuolation then those from L3 worms and, as with VacA treatment, adherent cells remained viable despite high levels of vacuolation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 1974 Sep 15;23 (18):2495-531 [4606365.001]
  • [Cites] Int J Parasitol. 1985 Apr;15(2):159-65 [3997348.001]
  • [Cites] J Infect Dis. 1990 Jun;161(6):1302-4 [2345308.001]
  • [Cites] Int J Parasitol. 1997 Jul;27(7):825-31 [9279586.001]
  • [Cites] J Parasitol. 1986 Apr;72(2):339-45 [3734999.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):245-50 [10448099.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4197-203 [8926088.001]
  • [Cites] Exp Parasitol. 1982 Dec;54(3):371-8 [6891337.001]
  • [Cites] Infect Immun. 1998 Aug;66(8):3981-4 [9673292.001]
  • [Cites] Int J Parasitol. 1996 Oct;26(10):1063-74 [8982786.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] J Physiol Pharmacol. 1993 Mar;44(1):17-22 [8518421.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):243-55 [11812622.001]
  • [Cites] Vet J. 2000 May;159(3):238-51 [10775468.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):C48-58 [9038810.001]
  • [Cites] Gut. 1992 Dec;33(12):1612-6 [1487161.001]
  • [Cites] J Parasitol. 1996 Apr;82(2):197-202 [8604083.001]
  • [Cites] Appl Biochem Biotechnol. 1991 Jul;30(1):29-41 [1952924.001]
  • [Cites] Vet Parasitol. 2000 Mar 28;89(1-2):79-94 [10729648.001]
  • [Cites] N Z Vet J. 1999 Feb;47(1):20-4 [16032062.001]
  • [Cites] Infect Immun. 1991 Apr;59(4):1264-70 [2004808.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):217-28 [11812620.001]
  • [Cites] J Biotechnol. 1996 May 15;46(3):161-85 [8672289.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G400-10 [10915650.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2943-50 [9596771.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):597 [3384991.001]
  • [Cites] J Parasitol. 1963 Aug;49:698-9 [14050253.001]
  • [Cites] Am J Physiol. 1990 May;258(5 Pt 1):G719-27 [2159239.001]
  • [Cites] J Cell Biol. 1981 Sep;90(3):656-64 [7287819.001]
  • [Cites] Am J Vet Res. 1981 Mar;42(3):498-502 [7271014.001]
  • [Cites] Gut. 1996 Dec;39(6):795-9 [9038659.001]
  • [Cites] Parasitol Res. 2005 Feb;95(3):213-7 [15723269.001]
  • [Cites] Scand J Gastroenterol. 1996 May;31(5):428-33 [8734337.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2829-33 [8698518.001]
  • [Cites] Infect Immun. 1990 Jun;58(6):1992-4 [2341188.001]
  • [Cites] Vet Parasitol. 1996 Apr;62(3-4):291-305 [8686175.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] Infect Immun. 1999 Aug;67(8):4237-42 [10417197.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • (PMID = 15918071.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Helminth Proteins
  •  go-up   go-down


28. Andersson A, Edén P, Lindgren D, Nilsson J, Lassen C, Heldrup J, Fontes M, Borg A, Mitelman F, Johansson B, Höglund M, Fioretos T: Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia; 2005 Jun;19(6):1042-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Leukemia / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Acute Disease. Burkitt Lymphoma / genetics. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Infant. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


29. Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H: An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica; 2008 Nov;93(11):1734-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
  • In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia.
  • Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial.
  • Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed.
  • Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 9. Sequence Deletion
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Mapping. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 22. Genetic Markers. Humans. Karyotyping. Leukocyte Count. Middle Aged. Prognosis. Survival Analysis. Translocation, Genetic. World Health Organization

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728022.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


30. Patte C, Ribrag V, Brugières L: [Non Hodgkin's lymphoma in adolescents]. Bull Cancer; 2007 Apr;94(4):339-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In France, adolescents (15-20 years) with non Hodgkin's lymphoma (NHL) are referred either to paediatric or to adult onco-haematological departments.
  • The categories of NHL that are reviewed and whose clinical and biological characteristics are presented are: Burkitt, lymphoblastic and large cell, either B or anaplastic.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Child. Clinical Protocols. France / epidemiology. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Medical Oncology / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449436.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 72
  •  go-up   go-down


31. Merks JH, Caron HN, Hennekam RC: High incidence of malformation syndromes in a series of 1,073 children with cancer. Am J Med Genet A; 2005 Apr 15;134A(2):132-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Constitutional molecular defects are known to play a role in oncogenesis, as shown by the increased incidence of embryonic cancers in children with Beckwith-Wiedemann syndrome (BWS) or of leukemia in children with Down syndrome.
  • We describe new syndrome-tumor associations in several entities: cleidocranial dysostosis (Wilms tumor), Bardet-Biedl syndrome (BBS) (acute lymphoblastic leukemia), Kabuki syndrome (neuroblastoma), LEOPARD syndrome (neuroblastoma), Poland anomaly (osteosarcoma; Hodgkin disease), and blepharophimosis epicanthus inversus syndrome (Burkitt lymphoma).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Comorbidity. DNA Methylation. Female. Genetic Predisposition to Disease / genetics. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Mutation. Netherlands / epidemiology. Syndrome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Am J Med Genet A. 2006 Apr 15;140(8):932 [16532461.001]
  • (PMID = 15712196.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Griskevicius L, Stulpinas R, Vengalyte I, Saulyte-Trakymiene S, Mickys U, Pranys D, Kurtinaitis J, Jurgutis M: Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia. Leuk Res; 2009 Apr;33(4):587-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Immunotherapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Child. Child, Preschool. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762337.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


33. Boerma EG, Siebert R, Kluin PM, Baudis M: Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia; 2009 Feb;23(2):225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.
  • Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants.
  • Within the core subset, no differences were found between pediatric and adult patients.
  • [MeSH-major] Burkitt Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923440.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


34. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • Of the malignant cases, there was a higher proportion of correct diagnosis based on morphology in the acute malignancies (67%) versus the chronic malignancies (47%).
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytological Techniques. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Bench AJ, Erber WN, Follows GA, Scott MA: Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. Int J Lab Hematol; 2007 Aug;29(4):229-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Burkitt Lymphoma / genetics. Gene Rearrangement. Humans. Immunoglobulin G / genetics. Leukemia, Hairy Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / genetics. Molecular Diagnostic Techniques. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617076.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 317
  •  go-up   go-down


37. Nomura S, Ishii K, Shimamoto Y, Yamamoto Y, Kadota E: Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier. Intern Med; 2006;45(4):215-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.
  • A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus.
  • Biopsies from abdominal operation were diagnosed as Burkitt lymphoma.
  • Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543692.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


38. Laudenschlager MD, Geis MC: An aggressive "double-hit" lymphoma occurring in a 42-year-old male with both MYC and t(14;18) translocations. S D Med; 2010 Sep;63(9):311-3, 315
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 42-year-old male who was in good health until he presented with a high grade B-cell non-Hodgkin lymphoma/leukemia that had both MYC and t(14;18) translocations.
  • This process has now been classified as "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma," according to the 2008 World Health Organization Classification of Tumours of Haematopoitic and Lymphoid Tissues.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Immunophenotyping. Karyotyping. Ki-67 Antigen / metabolism. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860118.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


39. Xie X, Xu W, Qiu H: [The cytogenetic features of Burkitt leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr;25(2):214-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The cytogenetic features of Burkitt leukemia].
  • OBJECTIVE: To evaluate the incidence of chromosomal abnormalities in Burkitt leukemia (BL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393250.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Choi KA, Lee JE, Kim YG, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W: Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol; 2009 Jul;88(7):639-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
  • Tumor lysis syndrome (TLS) is a potentially fatal metabolic complication of chemotherapy for Burkitt lymphoma.
  • This retrospective study evaluated the efficacy and safety of continuous venovenous hemofiltration (CVVH) with prephase chemotherapy using the modified LMB-89 regimen in patients with Burkitt lymphoma and leukemia (BL/L) at a high risk of developing TLS from February 1998 to February 2007.
  • Eight patients had Burkitt lymphoma and three had Burkitt leukemia; their median age was 48 years.
  • In conclusion, chemotherapy combined with CVVH might be effective and safe in patients with advanced Burkitt lymphoma and leukemia at a high risk of developing TLS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / therapy. Hemofiltration / methods. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hydrocortisone / administration & dosage. Hyperuricemia. Kidney Function Tests. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk. Survival Analysis. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030857.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


41. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF: Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant; 2006 Aug;38(3):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.
  • We explored the safety and efficacy of rituximab administered in combination with the standard transplant conditioning regimen of cyclophosphamide (Cy) 120 mg/kg and total body irradiation (TBI) 12 Gy for adult patients with acute lymphoblastic leukemia (ALL).
  • The cumulative incidence of grade II-IV acute GVHD was 17%, and limited and extensive chronic GVHD was 43% at 2 years.
  • The addition of rituximab to the standard Cy/TBI transplant conditioning regimen in ALL was safe and well tolerated, and there was a suggestion of decreased incidence of acute GVHD when compared to historically reported GVHD rates for this group of patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / therapy. Graft vs Host Disease / prevention & control. Immunologic Factors / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Chi-Square Distribution. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Middle Aged. Rituximab. Statistics, Nonparametric. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799614.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Callera F, Lopes CO, Rosa ES, Mulin CC: Adult transitional pre-B acute lymphoblastic leukemia associated with ring chromosome 16. Cancer Genet Cytogenet; 2008 Jun;183(2):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult transitional pre-B acute lymphoblastic leukemia associated with ring chromosome 16.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 16. Ring Chromosomes
  • [MeSH-minor] Adult. Female. Humans. Immunophenotyping


43. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


44. Teitell MA, Lones MA, Perkins SL, Sanger WG, Cairo MS, Said JW: TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma. Am J Clin Pathol; 2005 Oct;124(4):569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.
  • Elevated T-cell leukemia-1 (TCL1) oncoprotein expression might promote human Burkitt lymphoma (BL) because increased TCL1 causes Burkitt-like lymphomas in TCL1 transgenic mice.
  • However, persistent EBV is not essential for increased TCL1 expression, although elevated TCL1 and c-MYC coexpression might cooperate in the development of most pediatric and adult BL cases.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoid Tissue / metabolism. Proto-Oncogene Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146820.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107300; United States / NCI NIH HHS / CA / R01 CA90571
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TCL1A protein, human; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


45. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M: Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia; 2007 Apr;21(4):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients.
  • As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features.
  • [MeSH-major] Burkitt Lymphoma / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Telomere / ultrastructure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Allelic Imbalance. Disease-Free Survival. Humans. Immunoglobulin Variable Region. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis


46. Quijano S, López A, Rasillo A, Barrena S, Luz Sánchez M, Flores J, Fernández C, Sayagués JM, Osuna CS, Fernández N, González M, Giraldo P, Giralt M, Pérez MC, Martin-Antoran JM, Gutiérrez O, Perdiguer L, Díaz Mediavilla J, González Silva M, Asensio Del Rio A, Cerveró C, Guerra JL, Butrón R, García Mdel C, Almeida J, Orfao A: Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood; 2008 May 15;111(10):5130-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, proliferation of neoplastic B cells highly varied among the different B-CLPD subtypes, the greatest numbers of proliferating cells being identified in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).
  • Compared with normal B cells, neoplastic B-CLPD cells showed significantly increased S + G(2)/M-phase values in mantle cell lymphoma (MCL), B-chronic lymphocytic leukemia (B-CLL), BL, and some DLBCL cases.
  • Conversely, decreased proliferation was observed in follicular lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), and some DLBCL patients; hairy cell leukemia, splenic marginal zone, and MALT-lymphoma patients showed S + G(2)/M phase values similar to normal mature B lymphocytes from LN.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Female. Humans. Interphase. Kinetics. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337555.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, Poppema S, van den Berg A: Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer; 2006 Feb;45(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
  • We previously demonstrated high expression of primary-microRNA BIC (pri-miR-155) in Hodgkin lymphoma (HL) and lack of expression in most non-Hodgkin lymphoma subtypes including some Burkitt lymphoma (BL) cases.
  • Recently, high expression of BIC was reported in BL in comparison to pediatric leukemia and normal peripheral-blood samples.
  • [MeSH-major] Burkitt Lymphoma / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Blotting, Northern. Cell Line, Tumor. Child. Child, Preschool. Genes, myc. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235244.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


48. Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T, Koizumi T, Tatsumi E, Kumagai S: Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol; 2006;116(1):30-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
  • Peroxisome proliferator-activated receptor-gamma (PPARgamma), a member of the nuclear receptor superfamily, has been detected in several human leukemia cells.
  • We investigated the expression of PPARgamma and the effects of PPARgamma ligands on UTree-O2, Bay91 and 380, three B-cell acute lymphoblastic leukemia (B-ALL) cell lines with t(14;18), which show a poor prognosis, accompanying c-myc abnormality.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Burkitt Lymphoma / metabolism. Chromans / pharmacology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. G1 Phase / drug effects. PPAR gamma / biosynthesis. Thiazolidinediones / pharmacology. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Female. Gene Expression Regulation, Leukemic / drug effects. Humans. Ligands. Male. Prognosis. Proto-Oncogene Proteins c-myc / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction


49. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


50. Kaatsch P, Scheidemann-Wesp U, Schüz J: Maternal use of antibiotics and cancer in the offspring: results of a case-control study in Germany. Cancer Causes Control; 2010 Aug;21(8):1335-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Positive statistically significant associations with self-reported maternal antibiotic use were observed for acute lymphoid leukemia (based on 59 mothers exposed to antibiotics, OR = 1.47; 95% CI: 1.06-2.04), acute myeloid leukemia (18 exposed, OR = 3.21; 95% CI: 1.83-5.62), and Burkitt lymphoma (three exposed, OR = 5.89; 95% CI: 1.47-23.69), but not other cancer types.
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Female. Germany / epidemiology. Humans. Pregnancy. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20390445.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


51. Rastogi MV, Desai N, Quintos JB: Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. J Pediatr Endocrinol Metab; 2008 Aug;21(8):805-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma.
  • Lactic acidosis is likewise an uncommon complication of hematological malignancy associated mainly with leukemia and lymphoma.
  • Most cases of NICTH and lactic acidosis have been described in the adult population.
  • We report a child with congenital HIV and AIDS who developed Burkitt's lymphoma, lactic acidosis and NICTH.
  • PATIENT: An 11 year-old boy with AIDS, cerebral palsy and seizure disorder presented with intractable hypoglycemia 12 days after diagnosis of Burkitt's lymphoma.
  • [MeSH-major] Acidosis, Lactic / complications. Acidosis, Lactic / diagnosis. Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Hypoglycemia / complications. Hypoglycemia / diagnosis


52. Nisbet AJ, Bell NE, McNeilly TN, Knox DP, Maizels RM, Meikle LI, Wildblood LA, Matthews JB: A macrophage migration inhibitory factor-like tautomerase from Teladorsagia circumcincta (Nematoda: Strongylida). Parasite Immunol; 2010 Jul;32(7):503-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cDNA representing Tci-mif-1 was isolated following its identification in third-stage larvae (L3)-enriched cDNA population.
  • Messenger RNA (mRNA) representing the Tci-MIF-1 transcript was detected in eggs, L3 and adult stages of T. circumcincta.
  • Using immunohistochemistry, the Tci-MIF-1 protein was shown to have a diffuse distribution in L3 tissue, and in L4 and adult stages, the protein was localized to the nematode gut.
  • A recombinant version of Tci-MIF-1 was produced, and enzymic assays indicated that this recombinant protein and a somatic extract of L3 possessed dopachrome tautomerase activity as has been observed previously in other MIF-like molecules.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591121.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


53. Liu J, Hughes-Oliver JM, Menius JA Jr: Domain-enhanced analysis of microarray data using GO annotations. Bioinformatics; 2007 May 15;23(10):1225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our method, domain-enhanced analysis (DEA) is assessed and compared to other methods using simulation studies and analysis of two publicly available leukemia data sets.
  • [MeSH-major] Burkitt Lymphoma / genetics. Computational Biology. Leukemia-Lymphoma, Adult T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379692.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / 1 P20 HG003900-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


54. Khan NI, Bradstock KF, Bendall LJ: Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol; 2007 Aug;138(3):338-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia.
  • This study investigated the response of acute lymphoblastic leukaemia (ALL) cells to Wnt proteins.
  • Reverse transcription polymerase chain reaction (RT-PCR) analysis of B-cell progenitor acute lymphoblastic leukaemia (ALL) cells revealed expression of Wnt genes, including WNT2B in 33%, WNT5A in 42%, WNT10B in 58% and WNT16B in 25% of cases.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Gene Expression Regulation, Leukemic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Signal Transduction / physiology. Wnt Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adolescent. Adult. Apoptosis / genetics. Blotting, Western / methods. Cell Cycle Proteins / genetics. Child. Child, Preschool. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Wnt3 Protein. Wnt3A Protein

  • Guide to Pharmacology. gene/protein/disease-specific - FZD4 - data and references .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614820.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / beta Catenin
  •  go-up   go-down


55. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP, Chadburn A, Rafii S: Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Oct 1;12(19):5622-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Spatial localizations of vascular and stromal cells expressing CD34, VEGFR-1, alpha-SMA, and CD68 were examined by immunohistochemistry in 42 cases of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and compared with benign follicular hyperplasia.
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Microcirculation. Middle Aged. Muscle, Smooth / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020964.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 075234; United States / NHLBI NIH HHS / HL / HL 59312; United States / NHLBI NIH HHS / HL / HL 67839; United States / NCRR NIH HHS / RR / K23 RR 016814
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


56. Díaz-Camacho SP, Delgado-Vargas F, Willms K, de la Cruz-Otero Mdel C, Guadalupe Rendón-Maldonado J, Robert L, Antuna S, Nawa Y: Intrahepatic growth and maturation of Gnathostoma turgidum in the natural definitive opossum host, Didelphis virginiana. Parasitol Int; 2010 Sep;59(3):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results show that tiny (<3mm in length) third stage larvae (L3) appeared in the liver of opossums around November and December.
  • Also in the liver, we found large L3 of up to about 10mm in length together with juveniles and mature adults from February to March.
  • In spite of their length, large L3 have 4 rows of hooklets, and their gonads remained undeveloped.
  • Morphological features of the small and large L3 of G. turgidum are described including scanning electron microscope images.
  • The seasonal switching of the several growth stages of G. turgidum from small L3 to adult worms in the liver and eventual migration to the stomach in opossums suggests the unique feature of G. turgidum utilizing the liver as the maturation site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447468.001).
  • [ISSN] 1873-0329
  • [Journal-full-title] Parasitology international
  • [ISO-abbreviation] Parasitol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Helminth; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


57. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


58. Nelson BP, Treaba D, Goolsby C, Williams S, Dewald G, Gordon L, Peterson LC: Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum. Leuk Lymphoma; 2006 Jul;47(7):1352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum.
  • Precursor B-lymphoblastic leukemia is typically surface immunoglobulin (sIg) negative.
  • Although rare cases of sIg+ precursor lymphoblastic leukemia are recognized, sIg+ leukemia often represent leukemic phase of Burkitt lymphoma or other non-Hodgkin lymphoma such as blastic mantle cell lymphoma.
  • This study reports four adults, two women (56 and 58 years old) and two men (35 and 41 years old) with lymphoblastic leukemia that displayed lambda, surface immunoglobulin restriction (sIg+).
  • Genetic abnormalities were detected in all cases and in three cases included abnormalities commonly present in precursor lymphoblastic leukemia.
  • Deletion of the 3' region of the mixed lineage leukemia (MLL) gene at chromosome 11q23 as well as t(14;18) were detected in the second case.
  • Deletion of the 3' region of the mixed lineage leukemia (MLL) gene at chromosome 11q23 as well as t(14;18) were detected in one case.
  • These cases illustrate that lymphoblastic leukemias occurring in adults exhibit a morphologic, immunophenotypic as well as a genetic spectrum and represent either non-Hodgkin lymphoma or precursor lymphoblastic leukemia.
  • [MeSH-major] Immunoglobulins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Translocation, Genetic
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / metabolism. Burkitt Lymphoma / metabolism. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping / methods. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923568.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


59. Liu YR, Chen SS, Chang Y, Fu JY, Zhang LP, Wang H, Li LD, Zhu HH, Liu GL, Lu DP, Huang XJ: [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):853-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
  • To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).
  • There was no significantce different for incidence of LAIP between adult and pediatric patients.
  • It is concluded that in 90% of childhood and adult B-ALL patients LAIP can be found, which suits MRD detection by multiparameter flow cytometry.


60. Sánchez-García J, Serrano J, Gómez P, Martínez F, Martín C, Román-Gómez J, Rodríguez A, Herrera C, García JM, Alvarez MA, Torres A: The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica; 2006 Mar;91(3):340-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse.
  • However, mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly understood.
  • DESIGN AND METHODS: We used multiparameter flow-cytometry to quantify pro-B (CD19+CD10+CD34+), pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT.
  • RESULTS: Acute GVHD of grades II-IV is associated with a strong inhibition of normal donor-derived pro-B and pre-B precursors at days +30 and +60 post-SCT.
  • Likewise, recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chronic GVHD.
  • Induction of GVHD as treatment of increasing amounts of leukemia cells causes inhibition of both normal and malignant B compartments even in the absence of steroid therapy.
  • [MeSH-major] Burkitt Lymphoma / immunology. Graft vs Host Disease / immunology. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / pathology. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cell Lineage. Child. Child, Preschool. Chronic Disease. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Prospective Studies. Transplantation, Homologous


61. Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T: CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol; 2007 Sep 1;179(5):2880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.
  • In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-cell acute lymphocytic leukemia (B-ALL) CD23+CD5+ B cells.
  • [MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD5 / analysis. Child. Child, Preschool. Cytotoxicity, Immunologic. Female. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Proteins / antagonists & inhibitors. Proteins / genetics. Proteins / metabolism. RNA, Small Interfering / pharmacology. Receptors, IgE / analysis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2007 Nov 15;179(10):7184
  • (PMID = 17709502.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10
  •  go-up   go-down


62. Tagawa H: [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis]. Gan To Kagaku Ryoho; 2007 Jul;34(7):975-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We herein report the characteristic genomic alterations of malignant lymphomas including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and adult T cell lymphoma/leukemia (ATLL).
  • Comparison of genome profiles between acute type and lymphoma types of adult T cell lymphoma also demonstrated that acute and lymphoma types are genomically distinct subtypes, and thus may develop tumors via distinct genetic pathways.
  • [MeSH-major] Gene Dosage. Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Follicular / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Genome, Human. Humans. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637530.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


63. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW: Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma; 2009 Aug;9(4):307-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
  • Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens.
  • The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years.
  • We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature.
  • We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma;.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2232-3 [12805320.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Br J Haematol. 1989 Mar;71(3):371-6 [2930722.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):118-47 [17335683.001]
  • [Cites] Cancer Invest. 2007 Mar;25(2):87-93 [17453819.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5316-9 [18854560.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • (PMID = 19717381.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NCI NIH HHS / CA / CA031946-27; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NCI NIH HHS / CA / U10 CA031946; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / CA031946-28; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NHLBI NIH HHS / HL / HL007152; United States / NHLBI NIH HHS / HL / T32 HL007152-32; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA031946-27
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207721; NLM/ PMC2909640
  •  go-up   go-down


64. Higuchi M, Muta T, Karube KN, Eto T, Yamano Y, Ohshima K: Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report. Int J Hematol; 2007 Apr;85(3):219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive blastoid variant of mantle cell lymphoma in an adult with recurrent infectious mononucleosis-like symptoms: a case report.
  • Epstein-Barr virus (EBV) is closely associated with several lymphomas, such as Burkitt lymphoma, natural killer/T-cell lymphoma, peripheral T-cell lymphoma, and Hodgkin's lymphoma; however, whether EBV is implicated in mantle cell lymphoma (MCL) has not been established.
  • We report the case of an adult with recurrent infectious mononucleosis (IM)-like symptoms who developed an EBV-positive blastoid variant of MCL.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Infectious Mononucleosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):569-78 [11568749.001]
  • [Cites] Int J Hematol. 1998 Feb;67(2):165-74 [9631583.001]
  • [Cites] Blood. 2001 Jul 15;98(2):280-6 [11435294.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Intern Med. 2004 Oct;43(10):986-9 [15575253.001]
  • [Cites] J Virol. 1996 Dec;70(12):9003-7 [8971032.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Nature. 1970 Dec 12;228(5276):1056-8 [4320657.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):24-31 [12894847.001]
  • [Cites] Int J Hematol. 2000 Apr;71(3):259-62 [10846832.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Intern Med. 2005 Oct;44(10):1097-9 [16293926.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):194-9 [12827658.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]
  • (PMID = 17483058.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
  • The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).
  • Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas.
  • The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Gene Expression Regulation. Gene Expression Regulation, Leukemic. Hematopoietic Stem Cells / metabolism. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Humans. Middle Aged. Phenotype. Phosphorylation. Receptors, Antigen, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467082.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


66. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group: Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol; 2007 Sep;29(9):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
  • We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product.
  • Allergic reactions were significantly associated with younger age, white race, and standard-risk acute lymphoblastic leukemia.
  • [MeSH-major] Asparaginase / therapeutic use. Bacterial Proteins / therapeutic use. Burkitt Lymphoma / drug therapy. Escherichia coli / enzymology. Hypersensitivity / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Erwinia / enzymology. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Allergy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Sep;29(9):587-8 [17805029.001]
  • (PMID = 17805038.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-05587; United States / NCI NIH HHS / CA / CA-07431; United States / NCI NIH HHS / CA / CA-11233; United States / NCI NIH HHS / CA / CA-15525; United States / NCI NIH HHS / CA / CA-15898; United States / NCI NIH HHS / CA / CA-15989; United States / NCI NIH HHS / CA / CA-20549; United States / NCI NIH HHS / CA / CA-25408; United States / NCI NIH HHS / CA / CA-28383; United States / NCI NIH HHS / CA / CA-28439; United States / NCI NIH HHS / CA / CA-28476; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-29293; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-30969; United States / NCI NIH HHS / CA / CA-31566; United States / NCI NIH HHS / CA / CA-32053; United States / NCI NIH HHS / CA / CA-33587; United States / NCI NIH HHS / CA / CA-33603; United States / NCI NIH HHS / CA / CA-33625; United States / NCI NIH HHS / CA / CA-53128; United States / NCI NIH HHS / CA / CA-69177; United States / NCI NIH HHS / CA / CA-69428
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


67. Danilov AV, Pilichowska M, Danilova OV, Sprague KA: AIDS-related Burkitt lymphoma--a heterogeneous disease? Leuk Res; 2008 Dec;32(12):1939-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt lymphoma--a heterogeneous disease?
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Submandibular Gland Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization. Male. Mitosis. Phagocytosis. RNA, Messenger / genetics. RNA, Viral / genetics. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472158.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


68. Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH: Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol; 2006 May;85(5):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
  • Burkitt lymphoma/leukemia (BL) is a highly aggressive non-Hodgkin's lymphoma (NHL) often presenting in extranodal sites or as an acute leukemia.
  • Because of the shared molecular and genetic features, the World Health Organization classification of lymphoid diseases recognizes the lymphomatous and leukemic phases of BL as a single entity: a mature B cell neoplasm, subtype Burkitt lymphoma/Burkitt cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518604.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS, FAB/LMB96 International Study Committee: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood; 2007 Apr 1;109(7):2773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell).
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Remission Induction. Risk Factors. Survival Rate. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95 [1793154.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1396-402 [10780517.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):441-8 [11786572.001]
  • [Cites] Leukemia. 2002 Apr;16(4):594-600 [11960338.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):385-94 [15241838.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Sep;26(9):555-60 [15342981.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] J Chronic Dis. 1981;34(9-10):469-79 [7276137.001]
  • [Cites] J Chronic Dis. 1985;38(8):683-90 [4019705.001]
  • [Cites] J Clin Oncol. 1986 Aug;4(8):1219-26 [3525767.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):304-9 [2493074.001]
  • [Cites] Stat Med. 1989 Oct;8(10):1191-8 [2814068.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):526-33 [9324339.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • (PMID = 17132719.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol
  • [Other-IDs] NLM/ PMC1852229
  •  go-up   go-down


70. Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S231-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukemia: improving prognosis.
  • Burkitt lymphoma/leukemia (BL) has become a very curable mature B-cell neoplasm.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Child. Clinical Trials as Topic. Gene Expression Profiling. HIV Infections / complications. HIV Infections / drug therapy. Humans. Medical Oncology. Prognosis. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778846.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 47
  •  go-up   go-down


71. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


72. Burmeister T, Macleod RA, Reinhardt R, Mansmann V, Loddenkemper C, Marinets O, Drexler HG, Thiel E, Blau IW: A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement. Leuk Res; 2006 Nov;30(11):1417-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.
  • We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma.
  • Our findings are discussed in light of the current understanding of endemic and sporadic Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Line, Tumor. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 6 / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Cytogenetic Analysis / methods. HLA Antigens / genetics. Histocompatibility Testing. Humans. Immunohistochemistry. Immunophenotyping. Male. Oligonucleotide Array Sequence Analysis / methods

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697040.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


73. Kitamura N, Katagiri YU, Itagaki M, Miyagawa Y, Onda K, Okita H, Mori A, Fujimoto J, Kiyokawa N: The expression of granulysin in systemic anaplastic large cell lymphoma in childhood. Leuk Res; 2009 Jul;33(7):908-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of granulysin, a cytolytic protein produced by activated T and NK cells, has been revealed to be correlated with the prognosis of some adult cancer patients.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / genetics. Burkitt Lymphoma / genetics. Hodgkin Disease / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Antigens, CD / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Flow Cytometry. Humans. Killer Cells, Natural / metabolism. Killer Cells, Natural / pathology. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243819.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD96 antigen; 0 / GNLY protein, human; 0 / RNA, Messenger
  •  go-up   go-down


74. Mary KA, Hoti SL, Paily KP: Monoclonal antibodies generated against excretory/secretory antigens of mammalian stage larvae of the lymphatic filarial parasite Wuchereria bancrofti. J Immunoassay Immunochem; 2007;28(4):343-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five Mabs were obtained and, among them, Mab A7 showed high reactivity against e/s antigens of L4 and crude somatic antigens of microfilariae (mf) of W. bancrofti, and infective stage (L3) and adult stage larvae of Brugia malayi.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885888.001).
  • [ISSN] 1532-1819
  • [Journal-full-title] Journal of immunoassay & immunochemistry
  • [ISO-abbreviation] J Immunoassay Immunochem
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antibodies, Monoclonal; 0 / Antigens, Helminth
  •  go-up   go-down


75. Delaney A, Williamson A, Brand A, Ashcom J, Varghese G, Goud GN, Hawdon JM: Cloning and characterisation of an aspartyl protease inhibitor (API-1) from Ancylostoma hookworms. Int J Parasitol; 2005 Mar;35(3):303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using sequence from the hookworm expressed sequence tag project, specific primers were designed and used to amplify Ac-api-1 from A. caninum infective L3 cDNA by PCR.
  • The A. ceylanicum api-1 cDNA of 878 bp was cloned from L3 cDNA using the A. caninum primers.
  • Ac-api-1 mRNA was detected by reverse transcriptase PCR in eggs, L1, L3 and adult life cycle stages.
  • A polyclonal antiserum against Escherichia coli expressed recombinant Ac-API-1 detected the protein in adult A. caninum excretory/secretory products, but not in those from activated infective larvae.
  • Immunolocalisation experiments using the antiserum indicated that Ac-API-1 is present primarily in the pseudocoelomic fluid in adult hookworms.
  • Soluble, yeast-expressed Ac-API-1 failed to inhibit pepsin or a hookworm gut aspartyl protease in vitro, but inhibited approximately 30% of the proteolytic activity of adult excretory/secretory products.
  • The pseudocoleomic location, presence in all life cycle stages, lack of inhibitory activity against pepsin, and inhibitory activity against excretory/secretory products suggest that Ac-API-1 inhibits an unidentified, putative aspartyl protease secreted by adult hookworms, and may be released as an enzyme-inhibitor complex.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722082.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY705928/ AY705929
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases
  •  go-up   go-down


76. Gumy-Pause F, Wacker P, Maillet P, Betts DR, Sappino AP: ATM promoter analysis in childhood lymphoid malignancies: a brief communication. Leuk Res; 2006 Mar;30(3):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ATM promoter hypermethylation has been recently reported in adult carcinomas, but no information is available concerning the methylation status of ATM gene promoter in childhood B-precursor acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. DNA Methylation. DNA-Binding Proteins / genetics. Point Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Ataxia Telangiectasia Mutated Proteins. Carcinoma / genetics. Child. Child, Preschool. Female. Humans. Male. Sequence Analysis, DNA

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125772.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


77. Giacomin PR, Wang H, Gordon DL, Botto M, Dent LA: Loss of complement activation and leukocyte adherence as Nippostrongylus brasiliensis develops within the murine host. Infect Immun; 2005 Nov;73(11):7442-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Substantive deposition of C3 and adherence of eosinophil-rich leukocytes were seen with infective-stage (L3) but not with lung-stage (L4) larvae.
  • Adult intestinal worms had low to intermediate levels of both C3 and leukocyte binding.
  • For L3 and adult worms, complement deposition was principally dependent on the alternative pathway.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Trop Med Hyg. 1980 Sep;29(5):842-8 [7435788.001]
  • [Cites] Aust J Exp Biol Med Sci. 1979 Oct;57(5):459-66 [548018.001]
  • [Cites] Parasite Immunol. 1983 Mar;5(2):183-94 [6601790.001]
  • [Cites] Adv Parasitol. 1984;23:143-235 [6397977.001]
  • [Cites] Acta Trop. 1985 Jun;42(2):157-63 [2862778.001]
  • [Cites] Exp Parasitol. 1986 Feb;61(1):86-94 [3943595.001]
  • [Cites] Science. 1986 Oct 31;234(4776):603-7 [3094145.001]
  • [Cites] Parasite Immunol. 1987 Jan;9(1):133-43 [3550601.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1987 Mar;18(1):66-72 [3660070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] Exp Parasitol. 1988 Apr;65(2):157-67 [2450771.001]
  • [Cites] J Immunol. 1988 Jul 1;141(1):273-8 [3132503.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1987;82 Suppl 4:213-6 [2474124.001]
  • [Cites] Eur J Immunol. 1990 Jan;20(1):221-7 [2307175.001]
  • [Cites] J Parasitol. 1990 Jun;76(3):377-82 [2352068.001]
  • [Cites] Curr Opin Immunol. 2000 Feb;12(1):44-51 [10679403.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4544-51 [11035095.001]
  • [Cites] Exp Parasitol. 2000 Aug;95(4):231-9 [11038306.001]
  • [Cites] Parasite Immunol. 2001 Jan;23(1):27-37 [11136475.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1786-93 [12085326.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5604-11 [12228288.001]
  • [Cites] J Helminthol. 2003 Jun;77(2):119-24 [12756065.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6402-10 [14573661.001]
  • [Cites] Immunity. 2004 Mar;20(3):267-77 [15030771.001]
  • [Cites] Parasite Immunol. 2003 Nov-Dec;25(11-12):545-52 [15053775.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):201-10 [15251425.001]
  • [Cites] Infect Immun. 2004 Nov;72(11):6633-41 [15501796.001]
  • [Cites] J Cell Physiol. 1977 Mar;90(3):535-52 [856837.001]
  • [Cites] J Immunol. 1979 Oct;123(4):1551-7 [113459.001]
  • [Cites] Ann Trop Med Parasitol. 1990 Apr;84(2):185-91 [2200361.001]
  • [Cites] Int J Parasitol. 1990 Aug;20(5):587-93 [2228422.001]
  • [Cites] J Exp Med. 1990 Nov 1;172(5):1425-31 [2230651.001]
  • [Cites] Parasite Immunol. 1991 Jan;13(1):13-22 [2014134.001]
  • [Cites] Exp Parasitol. 1992 May;74(3):290-9 [1582481.001]
  • [Cites] Parasitology. 1993 Jun;106 ( Pt 5):463-9 [8341582.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4 [8524789.001]
  • [Cites] Parasitol Res. 1995;81(5):398-402 [7501639.001]
  • [Cites] J Immunol. 1996 Jul 15;157(2):549-56 [8752901.001]
  • [Cites] Parasite Immunol. 1995 Nov;17(11):555-9 [8817601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8720-5 [9238044.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:45-50 [9363925.001]
  • [Cites] Parasite Immunol. 1998 Feb;20(2):93-103 [9572052.001]
  • [Cites] Nat Genet. 1998 May;19(1):56-9 [9590289.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):989-93 [9916122.001]
  • [Cites] Infect Immun. 1999 Oct;67(10):5315-23 [10496911.001]
  • [Cites] J Immunol. 1980 Jun;124(6):2886-91 [6989909.001]
  • [Cites] J Pathol. 1981 Feb;133(2):161-75 [7205445.001]
  • (PMID = 16239545.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 80295-33-6 / Complement C1q; EC 3.4.21.47 / Complement Factor B
  • [Other-IDs] NLM/ PMC1273855
  •  go-up   go-down


78. Babusíková O, Zelezníková T, Mlcáková A, Kusenda J, Stevulová L: The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia. Neoplasma; 2005;52(6):502-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
  • Increased information on benign B-lymphocyte precursors, especially that of existence of the 3rd type hematogones could provide a basis for better discrimination of B-leukemia cells even in a very small amounts.
  • [MeSH-major] Antigens, CD / analysis. B-Lymphocytes / immunology. Bone Marrow / immunology. Bone Marrow Cells / cytology. Burkitt Lymphoma / diagnosis. Immunophenotyping
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Middle Aged. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284697.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


79. D'Achille P, Seymour JF, Campbell LJ: Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet; 2006 Nov;171(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
  • We present a series of 12 cases of de novo acute lymphoblastic leukemia (ALL) with translocation t(14;18)(q32;q21).
  • A Burkitt translocation was identified in 4 of the 12 cases by conventional cytogenetics but fluorescence in situ hybridization using a MYC probe identified a further three cases of MYC rearrangement: one with a cryptic t(8;14) involving the der(14)t(14;18), one showing MYC translocated onto a marker chromosome, and one associated with a t(8;9)(q24;p13) translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD19 / analysis. Antigens, CD20 / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neprilysin / analysis. Sialic Acid Binding Ig-like Lectin 2 / analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074591.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Sialic Acid Binding Ig-like Lectin 2; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 32
  •  go-up   go-down


80. Brand AM, Varghese G, Majewski W, Hawdon JM: Identification of a DAF-7 ortholog from the hookworm Ancylostoma caninum. Int J Parasitol; 2005 Dec;35(14):1489-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infective hookworm L3 encounter a host specific signal during invasion that re-activates suspended developmental pathways.
  • In the free-living nematode Caenorhabditis elegans, recovery from the developmentally arrested dauer stage in response to environmental cues is analogous to the resumption of development in invading hookworm L3.
  • An insulin-like signalling pathway mediates L3 activation in hookworms.
  • Sequence from a hookworm expressed sequence tag was used to design specific primers for PCR amplification of Ac-daf-7 from Ancylostoma caninum infective L3 cDNA.
  • Ac-daf-7 mRNA was strongly detected by reverse transcriptase PCR in L3 and serum stimulated L3 cDNA, and weakly in cDNA from L1 and adult life cycle stages.
  • Antiserum against Escherichia coli expressed recombinant Ac-DAF-7 detected the mature protein in L3 and adult soluble extracts, but not in excretory/secretory products from serum stimulated L3 or adults.
  • Increased expression in arrested L3 stages suggests that Ac-daf-7 is important for developmental arrest.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135366.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ058687/ DQ059758
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Caenorhabditis elegans Proteins; 0 / DAF-7 protein, C elegans; 0 / Transforming Growth Factor beta
  •  go-up   go-down


81. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, Dastugue N, Brousset P: A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood; 2007 Apr 15;109(8):3417-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
  • We report a novel t(7;9)(q11;p13) translocation in 2 patients with B-cell acute lymphoblastic leukemia (B-ALL).
  • After cloning the full-length cDNA of the chimeric gene, confocal microscopy of transfected NIH3T3 cells and Burkitt lymphoma cells (DG75) demonstrated that PAX5-ELN was localized in the nucleus.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Elastin / genetics. Genes, Dominant. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Animals. Antigens, CD19 / biosynthesis. Antigens, CD19 / genetics. Cell Differentiation / genetics. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. HeLa Cells. Humans. Male. Mice. NIH 3T3 Cells. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179230.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 9007-58-3 / Elastin
  •  go-up   go-down


82. Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B, Desablens B, Lefrère JJ, Gouilleux F, Lassoued K, Gouilleux-Gruart V: ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica; 2005 Jul;90(7):899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
  • While little is known about ZAP-70 expression in normal human B cells, it has been reported that ZAP-70 is expressed in a subset of patients with chronic lymphocytic leukemia (CLL) with a poor prognosis.
  • In this study, we examined the expression and phosphorylation status of ZAP-70 in B-lineage acute lymphoblastic leukemia (Blin-ALL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Gene Expression Regulation, Neoplastic. ZAP-70 Protein-Tyrosine Kinase / biosynthesis. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Bone Marrow / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Phosphorylation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Jul;90(7):867 [15996917.001]
  • (PMID = 15996927.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


83. Don TA, Oksov Y, Lustigman S, Loukas A: Saposin-like proteins from the intestine of the blood-feeding hookworm, Ancylostoma caninum. Parasitology; 2007 Mar;134(Pt 3):427-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both Ac-slp-1 and slp-2 mRNAs were shown to be expressed in all life stages assessed, with slp-1 predominantly being expressed in third-stage larvae (L3) before and after activation with dog serum.
  • These antisera were used as probes in fluorescence microscopy to localize the anatomic expression sites of both proteins to small, punctate organelles or vesicles within the intestinal cells of adult worms; weak staining was detected on the microvillar brush border of the intestine.
  • Using transmission electron microscopy, both proteins were localized to similar vesicles in the intestinal cells of the L3.
  • Their expression in the gut of the L3 and adult stages suggests a role for these hookworm SAPLIPs in the lysis of host cells during tissue migration and/or feeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109779.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Helminth Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Saposins
  •  go-up   go-down


84. Bricarello PA, Zaros LG, Coutinho LL, Rocha RA, Silva MB, Kooyman FN, De Vries E, Yatsuda AP, Amarante AF: Immunological responses and cytokine gene expression analysis to Cooperia punctata infections in resistant and susceptible Nelore cattle. Vet Parasitol; 2008 Aug 1;155(1-2):95-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum IgG1 mean levels against C. punctata antigens were higher in the resistant group, but significant differences between groups were only observed 14 days after the beginning of the experiment against infective larvae (L3) and 14 and 84 days against adult antigens.
  • The resistant group also presented higher IgA levels against C. punctata (L3 and adult) antigens with significant difference 14 days after the beginning of the trial (P<0.05).
  • In the small-intestine mucosa, levels of IgA anti-L3 and anti-adult C. punctata were higher in the resistant group, compared with the susceptible group (P<0.05).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513872.001).
  • [ISSN] 0304-4017
  • [Journal-full-title] Veterinary parasitology
  • [ISO-abbreviation] Vet. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulin A
  •  go-up   go-down


85. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ: Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res; 2010 May 15;70(10):3915-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
  • Allogeneic hematopoietic stem-cell transplantation can cure some patients with high-risk B-cell malignancies, but disease relapse following transplantation remains a significant problem.
  • One approach that could be used to augment the donor T-cell-mediated antitumor effect is the infusion of allogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell antigen CD19.
  • However, the use of such cells might result in toxicity in the form of graft-versus-host disease mediated by CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors.
  • We therefore investigated whether nonalloreactive tumor-specific human T cells could be generated from peripheral blood mononuclear cells of healthy donors by the combination of CD19 redirection via CAR expression and subsequent alloanergization by allostimulation and concomitant blockade of CD28-mediated costimulation.
  • Alloanergization of CD19-CAR T cells resulted in efficient and selective reduction of alloresponses in both CD4(+) and CD8(+) T cells, including allospecific proliferation and cytokine secretion.
  • Importantly, T-cell effector functions including CAR-dependent proliferation and specific target cytolysis and cytokine production were retained after alloanergization.
  • Our data support the application of CD19 redirection and subsequent alloanergization to generate allogeneic donor T cells for clinical use possessing increased antitumor activity but limited capacity to mediate graft-versus-host disease.
  • Immunotherapy with such cells could potentially reduce disease relapse after allogeneic transplantation without increasing toxicity, thereby improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignancies.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Blood. 2002 Jun 15;99(12):4357-63 [12036862.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):825-33 [17299405.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2292-9 [12763937.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1375-7 [14585640.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1158-65 [14525783.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Transplantation. 2004 Sep 27;78(6):815-24 [15385799.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2403-9 [15231569.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] J Immunol. 1983 Jul;131(1):244-50 [6408173.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Transplantation. 1990 Jul;50(1):1-7 [2142343.001]
  • [Cites] J Exp Med. 1993 Jan 1;177(1):165-73 [7678111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6586-90 [7688125.001]
  • [Cites] J Immunol. 1996 May 15;156(10):3587-90 [8621891.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4887-93 [8639863.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2620-30 [17507664.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):294-305 [18060041.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):580-9 [18227839.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4392-402 [17878399.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2961-71 [18413766.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22 [18721776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1515-6 [18725873.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2232-41 [18617635.001]
  • [Cites] Transplantation. 2008 Sep 27;86(6):854-64 [18813111.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1264-70 [18978797.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1453-64 [19384291.001]
  • [Cites] Gene Ther. 2009 Aug;16(8):1042-9 [19494842.001]
  • [Cites] N Engl J Med. 1999 Jun 3;340(22):1704-14 [10352162.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3429-36 [15284108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17312-5 [15574496.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 May;11(5):362-70 [15846290.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):7046-52 [16272366.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1889-92 [17041638.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Nat Biotechnol. 2002 Dec;20(12):1221-7 [12415288.001]
  • (PMID = 20424114.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120956-01A1; United States / NCI NIH HHS / CA / R01 CA141303; United States / NCI NIH HHS / CA / R01 CA124782-01A1; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA124782; United States / NCI NIH HHS / CA / CA124782-03S2; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / R21 CA116127-01A1; United States / NCI NIH HHS / CA / R21S CA116127; United States / NCI NIH HHS / CA / P01 CA100265; United States / NCI NIH HHS / CA / 5P30CA016672-32; United States / NCI NIH HHS / CA / R01S CA120956; United States / NCI NIH HHS / CA / R01S CA124782; United States / NCI NIH HHS / CA / CA116127-01A1; United States / NCI NIH HHS / CA / R21S CA129390; United States / NCI NIH HHS / CA / R21S CA137645; United States / NCI NIH HHS / CA / R21 CA129390; United States / NCI NIH HHS / CA / U19 CA100265; United States / NCI NIH HHS / CA / R01 CA124782-03S2; United States / NCI NIH HHS / CA / R21 CA116127; United States / NCI NIH HHS / CA / CA124782-01A1; United States / NCI NIH HHS / CA / R33 CA116127; United States / NCI NIH HHS / CA / R01 CA120956-01A1; United States / NCI NIH HHS / CA / R21 CA137645; United States / NCI NIH HHS / CA / R01 CA120956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19
  • [Other-IDs] NLM/ NIHMS188106; NLM/ PMC2873153
  •  go-up   go-down


86. García-Coiradas L, Angulo-Cubillán F, Méndez S, Larraga V, de la Fuente C, Cuquerella M, Alunda JM: Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus. Parasitol Res; 2009 Jan;104(2):363-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus.
  • The putative protective antigen, p26/23, from adult Haemonchus contortus was isolated.
  • A soluble extract from adult helminths obtained from the abomasa of hyperinfected (12,000 infective larvae) female Manchego lambs and treated with a mixture of protease inhibitors was subjected to affinity chromatography (hexylgluthatione) to eliminate the enzyme gluthatione S-transferase.
  • This allowed the isolation of a single protein, which was expressed in both infective larvae (L3) and the adult stage of the parasite.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Parasitol Res. 1998 Aug;84(8):623-31 [9747934.001]
  • [Cites] Exp Parasitol. 1998 Jan;88(1):34-42 [9501846.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):4762-7 [7927752.001]
  • [Cites] Parasitol Res. 2000 Mar;86(3):200-6 [10726990.001]
  • [Cites] Methods Mol Biol. 1992;10:7-12 [23150291.001]
  • [Cites] Parasite Immunol. 2003 May;25(5):283-96 [12969446.001]
  • [Cites] Parasitology. 1997 Mar;114 ( Pt 3):293-9 [9075348.001]
  • [Cites] Trends Parasitol. 2004 Oct;20(10):469-76 [15363440.001]
  • [Cites] Vaccine. 2004 Jan 26;22(5-6):618-28 [14741153.001]
  • [Cites] Rev Sci Tech. 2007 Apr;26(1):105-15 [17633296.001]
  • [Cites] Parasite Immunol. 2000 Mar;22(3):131-8 [10672194.001]
  • [Cites] Br J Nutr. 1988 Jan;59(1):125-39 [3257884.001]
  • [Cites] Int J Parasitol. 2001 Mar;31(3):231-44 [11226449.001]
  • [Cites] Int J Parasitol. 2004 Aug;34(9):1037-45 [15313130.001]
  • [Cites] Mol Biochem Parasitol. 1997 Sep;88(1-2):203-13 [9274880.001]
  • [Cites] Am J Vet Res. 1984 Feb;45(2):230-3 [6608886.001]
  • [Cites] Mol Biochem Parasitol. 1998 Mar 15;91(2):221-35 [9566516.001]
  • [Cites] Parasite Immunol. 1997 Oct;19(10):447-53 [9372512.001]
  • [Cites] Int J Parasitol. 1987 Feb;17(2):443-51 [3294656.001]
  • [Cites] Parasite Immunol. 1999 Apr;21(4):201-10 [10320617.001]
  • [Cites] Br Vet J. 1990 Nov-Dec;146(6):543-50 [2271911.001]
  • [Cites] Int J Parasitol. 1997 Apr;27(4):359-66 [9184927.001]
  • [Cites] Vet Parasitol. 1991 Mar;38(2-3):131-43 [1858283.001]
  • [Cites] Parasitology. 1993 Jan;106 ( Pt 1):63-6 [8479802.001]
  • [Cites] Int J Parasitol. 1993 Apr;23(2):261-9 [8496009.001]
  • [Cites] Parasitology. 2000;120 Suppl:S95-107 [10874713.001]
  • [Cites] Trop Med Int Health. 1997 May;2(5):472-81 [9217703.001]
  • [Cites] Int J Parasitol. 1991 Nov;21(7):839-46 [1774119.001]
  • [Cites] J Infect Dis. 2003 Feb 1;187(3):484-94 [12552433.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1645-50 [8576165.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] Anal Biochem. 1977 Oct;82(2):334-41 [907137.001]
  • [Cites] Vet Parasitol. 1997 Nov;72(3-4):285-97; discussion 297-308 [9460203.001]
  • [Cites] Am J Vet Res. 1992 Jul;53(7):1263-5 [1497200.001]
  • (PMID = 18825413.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth
  •  go-up   go-down


87. Fey MF: [Salient clinical features of lymphoma and related lymphoproliferative disorders]. Ther Umsch; 2010 Oct;67(10):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Biopsy. Burkitt Lymphoma / classification. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Diagnosis, Differential. Enteropathy-Associated T-Cell Lymphoma / classification. Enteropathy-Associated T-Cell Lymphoma / diagnosis. Enteropathy-Associated T-Cell Lymphoma / pathology. Female. Hodgkin Disease / classification. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / classification. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Waldenstrom Macroglobulinemia / classification. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886453.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


88. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, Tan W: Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem; 2007 Apr 15;79(8):3075-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aptamers, Nucleotide / chemistry. Burkitt Lymphoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, B-Cell / pathology. Nanoparticles / chemistry. SELEX Aptamer Technique / methods

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348633.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Fluorescent Dyes
  •  go-up   go-down


89. Simcock DC, Brown S, Neale JD, Przemeck SM, Simpson HV: L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake. Exp Parasitol; 2006 Jan;112(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake.
  • Oxygen consumption by L3 and adult Ostertagia (Teladorsagia) circumcincta was examined in vitro to determine whether oxygen can be utilised in metabolism.
  • Rates of consumption (in nmol O2/h/1000 worms) were 13+/-1 in sheathed L3, 34+/-6 in ex-sheathed L3, and 1944+/-495 in adult worms.
  • Consumption was inhibited 95% by cyanide in L3 and 74% in adults.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM CYANIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198342.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose; MQD255M2ZO / Potassium Cyanide; S88TT14065 / Oxygen
  •  go-up   go-down


90. Magrath IT: Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. Curr Hematol Malig Rep; 2006 Dec;1(4):230-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
  • Modern chemotherapy for childhood Burkitt lymphoma has its origins in Africa, where treatment evolved from one or two doses of single agents, which were curative in some patients, to combinations of non-cross-resistant drugs.
  • Therapy regimens for adults with Burkitt lymphoma have been developed by modifying second-generation pediatric protocols, and few investigators have used the third-generation pediatric regimens that include higher doses of methotrexate and additional agents.
  • Because childhood diffuse large-B-cell leukemia (DLBCL) responds equally well to therapy for Burkitt lymphoma, more intensive therapy and intensive support might also give better results in at least a subset of adults with advanced DLBCL-perhaps defined on the basis of limited molecular profiling, which has provided new information about the categories of aggressive B-cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Age Factors. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System / pathology. Child. Diagnosis, Differential. Drug Therapy / trends. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Rituximab. Salvage Therapy. Treatment Outcome. Uganda / epidemiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1967 May;20(5):756-9 [6024288.001]
  • [Cites] Br Med J. 1967 Nov 11;4(5575):323-7 [6053614.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] N Engl J Med. 1977 Jul 14;297(2):75-80 [865579.001]
  • [Cites] Onkologie. 1986 Apr;9(2):126-30 [3520421.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Med Pediatr Oncol. 2001 Nov;37(5):432-41 [11745871.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Blood. 1984 May;63(5):1102-11 [6546890.001]
  • [Cites] Cancer. 1978 Mar;41(3):1059-63 [638947.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):538-9 [14998863.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Pediatr Hematol Oncol. 1986;3(1):11-8 [3153214.001]
  • [Cites] Leukemia. 2005 Apr;19(4):659-63 [15716988.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:77-81 [9187436.001]
  • [Cites] Int J Cancer. 1972 Sep 15;10(2):254-61 [4574467.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):240-8 [8558204.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1973-82 [1941056.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):115-21 [15350300.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):353-8 [14735176.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4244 [14623773.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Med Oncol. 2005;22(3):257-67 [16110137.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 1988 Aug;72(2):792-5 [3401598.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):285-91 [11900213.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Leuk Res. 1980;4(1):33-59 [6968008.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):436-40 [776840.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] JAMA. 1972 Nov 27;222(9):1166 [4678054.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Br Med J. 1971 Aug 26;3(5773):508-12 [5109411.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):211-9 [1703226.001]
  • [Cites] Am J Med. 1975 Mar;58(3):314-21 [1115074.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):661-5 [2313335.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1977 Jun;16(3):225-31 [906892.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):815-20 [15352985.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Hematol Oncol. 1991 Jul-Oct;9(4-5):267-74 [1743629.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2465-72 [8823324.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Cancer. 1976 Sep;38(3):1043-51 [782684.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Cancer. 1970 Aug;26(2):474-84 [5468593.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2578-615 [6082297.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Haematol Blood Transfus. 1977;20:297-305 [580252.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • (PMID = 20425318.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 78
  •  go-up   go-down


91. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med; 2006 Jun 8;354(23):2431-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of Burkitt's lymphoma.
  • BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
  • We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma.
  • Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes.
  • Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods.
  • Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
  • CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Gene Expression. Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bayes Theorem. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Genes, MHC Class I. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. NF-kappa B / genetics. Oligonucleotide Array Sequence Analysis. Survival Analysis. Transcription, Genetic. Translocation, Genetic


92. Su XY, Xu X, Tang Y, Li GD: [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):542-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 33 cases of hematolymphoid malignancy, including 12 cases of T-lymphoblastic leukemia/lymphoma, 16 cases of mature B cell neoplasm (including 9 cases of diffuse large B-cell lymphoma, 2 cases of Burkitt lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma and 1 case of mantle cell lymphoma), 3 cases of mature T or NK-cell neoplasm (including 1 case of extranodal nasal NK/T-cell lymphoma, 1 case of angioimmunoblastic T-cell lymphoma and 1 case of T-cell prolymphocytic leukemia), 1 case of myeloid sarcoma and 1 case of mast cell sarcoma.
  • Amongst the 33 cases studied, 16 represented disease relapses, including 8 cases of diffuse large B-cell lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma, 1 case of T-lymphoblastic leukemia/lymphoma, 1 case of angioimmunoblastic T-cell lymphoma, 1 case of mantle cell lymphoma and 1 case of mast cell sarcoma.
  • [MeSH-major] Ascitic Fluid / pathology. Cytodiagnosis / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Plasmacytoma / diagnosis. Plasmacytoma / metabolism. Plasmacytoma / pathology. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021966.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E: Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia; 2005 Aug;19(8):1391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.
  • Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL).
  • We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(2;8)(p11;q24) and t(8;22)(q24;q11).
  • A typical L3 or L3-compatible cytomorphology was highly predictive (>80%) but not specific of a MYC translocation.
  • [MeSH-major] Burkitt Lymphoma / genetics. Genetic Heterogeneity. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Cytogenetic Analysis. Female. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Polymerase Chain Reaction. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1391-1398.
  • (PMID = 15973450.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


94. Coche D, Bergues B, Harrivel V, Guillaume N: [Biphenotypic acute leukaemia with Burkitt-like cytology]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):437-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia with Burkitt-like cytology].
  • [Transliterated title] Leucémie aiguë biphénotypique avec aspect cytologique de type Burkitt.
  • Biphenotypic acute leukaemia (BAL) represents about 5% of adult acute leukaemia.
  • Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the acute lymphoblastic leukaemia, Burkitt type" L3 for the FAB classification.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / genetics
  • [MeSH-minor] Adult. Blast Crisis / pathology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654084.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


95. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S: Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia; 2009 Nov;23(11):2090-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
  • Unfortunately, however, tumors including adult T-cell leukemia/lymphoma (ATL) have disadvantages such as p53 mutations and a lack of p16(INK4a) and/or p14(ARF).
  • In this study we characterized Nutlin-3a-induced cell death in 16 leukemia/lymphoma cell lines.
  • [MeSH-major] Apoptosis / drug effects. Imidazoles / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Piperazines / pharmacology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Cell Aging / drug effects. Cell Cycle / drug effects. Cell Line, Transformed. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Drug Synergism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Jurkat Cells. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. RNA, Small Interfering. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Tumor Suppressor Protein p14ARF / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710698.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C12orf5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Imidazoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


96. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, Ruminy P, Picquenot JM, Tilly H: Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia; 2007 Mar;21(3):515-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal translocations joining the immunoglobulin (IG) and MYC genes have been extensively reported in Burkitt's and non-Burkitt's lymphomas but data concerning MYC rearrangements with non-IG partners are scarce.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Cell-Specific Activator Protein / genetics. Base Sequence. Burkitt Lymphoma / genetics. Carrier Proteins / genetics. Cell Transformation, Neoplastic / genetics. Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 2 / ultrastructure. Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 3 / ultrastructure. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 7 / ultrastructure. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / ultrastructure. DNA-Binding Proteins / genetics. Female. Humans. Ikaros Transcription Factor / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Molecular Sequence Data. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230227.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BCL11A protein, human; 0 / BCL6 protein, human; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / IKZF1 protein, human; 0 / Nuclear Proteins; 0 / PAX5 protein, human; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


97. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


98. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG: An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol; 2010 Feb;148(4):600-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
  • Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with short intensive treatment regiments.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Cytogenet Cell Genet. 1989;52(3-4):136-8 [2630185.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):22-4 [1423221.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6547-52 [1330296.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):199-205 [7685621.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):282-7 [7519050.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1925-30 [10706856.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):179-83 [12930318.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] J Pathol. 2004 Aug;203(4):940-5 [15258997.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):965-9 [15291356.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1595-603 [15370211.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):482-6 [844916.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Leukemia. 2009 Feb;23(2):323-31 [19020548.001]
  • [Cites] Eur J Cancer. 1981 May;17(5):577-84 [6271555.001]
  • (PMID = 19895612.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS163764; NLM/ PMC2921871
  •  go-up   go-down


99. Raina V, Medhi K, Kataria S, Kumar R, Chopra A, Kalita D, Kadam PA: Burkitt's leukemia after treatment of primary mediastinal nonseminomatous germ cell tumor. J Clin Oncol; 2008 May 1;26(13):2212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's leukemia after treatment of primary mediastinal nonseminomatous germ cell tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / pathology. Carcinoma, Embryonal / therapy. Mediastinal Neoplasms / therapy. Teratoma / therapy
  • [MeSH-minor] Adult. Fatal Outcome. Gene Expression Regulation, Neoplastic. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A: Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest; 2009 Dec;89(12):1364-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical examination found that diffuse large B-cell lymphoma (10/21, 48%) and Burkitt lymphoma (BL) (6/7, 86%) cells highly (percentage of positive cells, >20%) expressed Aurora B in their nuclei.
  • Exposure of BL/leukemia cells to AZD1152-HQPA in vitro, a selective inhibitor of Aurora B kinase, potently induced growth arrest and apoptosis in a caspase-dependent, as well as -independent manner.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Aurora Kinase B. Aurora Kinases. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Synergism. Enzyme Activation. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Middle Aged. Organophosphates / pharmacology. Phosphorylation. Quinazolines / pharmacology. Signal Transduction / drug effects. Tubulin Modulators / pharmacology. Vincristine / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823168.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 0 / Organophosphates; 0 / Quinazolines; 0 / Tubulin Modulators; 5J49Q6B70F / Vincristine; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down






Advertisement